candesartan cilexetil has been researched along with Albuminuria in 15 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
Excerpt | Relevance | Reference |
---|---|---|
"CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 9.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
"These findings suggest that the low-dose combination therapy of nifedipine CR and candesartan is superior to the up-titrated monotherapy of candesartan in terms of blood pressure control and renal protection in patients with essential hypertension." | 9.11 | Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. ( Hasebe, N; Kikuchi, K, 2005) |
"CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 5.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
"These findings suggest that the low-dose combination therapy of nifedipine CR and candesartan is superior to the up-titrated monotherapy of candesartan in terms of blood pressure control and renal protection in patients with essential hypertension." | 5.11 | Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. ( Hasebe, N; Kikuchi, K, 2005) |
"Fifty-two patients with type 2 diabetes with normo- and microalbuminuria participated in this study." | 2.71 | Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. ( Adachi, M; Hirano, T; Ikejiri, R; Murayama, S; Okada, K; Sakaue, T, 2003) |
"Many patients with diabetic nephropathy (DN) have levels of albuminuria > 1 g/day and blood pressure >135/85 mmHg, despite antihypertensive combination therapy, including recommended doses of ACE inhibitors, e." | 2.70 | Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. ( Christensen, PK; Jensen, BR; Parving, HH; Rossing, K, 2002) |
"Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system." | 2.47 | Differential clinical profile of candesartan compared to other angiotensin receptor blockers. ( Cernes, R; Mashavi, M; Zimlichman, R, 2011) |
" RI was compared to the ARB, candesartan (3 mg/kg/day PO), and to the ACEI, enalapril (60 mg/kg/day PO) in a 4-week dosing paradigm." | 1.35 | A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. ( Carlson, T; Kowala, MC; Leadley, R; Major, TC; Okerberg, C; Olszewski, B; Ostroski, R; Rosebury, W; Schroeder, R, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (26.67) | 18.2507 |
2000's | 8 (53.33) | 29.6817 |
2010's | 3 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hayashi, K | 2 |
Sasamura, H | 1 |
Nakamura, M | 1 |
Sakamaki, Y | 1 |
Azegami, T | 1 |
Oguchi, H | 1 |
Tokuyama, H | 1 |
Wakino, S | 1 |
Itoh, H | 1 |
Major, TC | 1 |
Olszewski, B | 1 |
Rosebury, W | 1 |
Okerberg, C | 1 |
Carlson, T | 1 |
Ostroski, R | 1 |
Schroeder, R | 1 |
Kowala, MC | 1 |
Leadley, R | 1 |
Ketelhut, R | 1 |
Bramlage, P | 1 |
Cernes, R | 1 |
Mashavi, M | 1 |
Zimlichman, R | 1 |
Murayama, S | 1 |
Hirano, T | 1 |
Sakaue, T | 1 |
Okada, K | 1 |
Ikejiri, R | 1 |
Adachi, M | 1 |
Kakizawa, H | 1 |
Itoh, Y | 1 |
Imamura, S | 1 |
Matsumoto, T | 1 |
Ishiwata, Y | 1 |
Ono, Y | 1 |
Yamamoto, K | 1 |
Kato, T | 1 |
Hayakawa, N | 1 |
Oda, N | 1 |
Goto, Y | 2 |
Nagasaka, A | 1 |
Senda, T | 1 |
Itoh, M | 1 |
Rosei, EA | 1 |
Rizzoni, D | 1 |
Muiesan, ML | 1 |
Sleiman, I | 1 |
Salvetti, M | 1 |
Monteduro, C | 1 |
Porteri, E | 1 |
Hasebe, N | 1 |
Kikuchi, K | 1 |
Kim, S | 1 |
Ohta, K | 1 |
Hamaguchi, A | 1 |
Omura, T | 1 |
Yukimura, T | 1 |
Miura, K | 1 |
Inada, Y | 1 |
Wada, T | 1 |
Ishimura, Y | 2 |
Chatani, F | 1 |
Kohara, K | 1 |
Mikami, H | 1 |
Okuda, N | 1 |
Higaki, J | 1 |
Ogihara, T | 1 |
Obata, J | 1 |
Nakamura, T | 2 |
Kuroyanagi, R | 1 |
Yoshida, Y | 1 |
Guo, DF | 1 |
Inagami, T | 1 |
Casellas, D | 1 |
Benahmed, S | 1 |
Artuso, A | 1 |
Jover, B | 1 |
Ushiyama, C | 1 |
Suzuki, S | 1 |
Shimada, N | 1 |
Sekizuka, K | 1 |
Ebihara, I | 1 |
Takahashi, Y | 1 |
Tanaka, A | 1 |
Koide, H | 1 |
Rossing, K | 1 |
Christensen, PK | 1 |
Jensen, BR | 1 |
Parving, HH | 1 |
Matsuo, T | 1 |
Ishikawa, E | 1 |
Ohta, M | 1 |
Shibouta, Y | 1 |
Imura, Y | 1 |
Sugiyama, Y | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for candesartan cilexetil and Albuminuria
Article | Year |
---|---|
Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Biphenyl Compounds; | 2011 |
6 trials available for candesartan cilexetil and Albuminuria
Article | Year |
---|---|
Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diab | 2010 |
Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2003 |
Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2005 |
Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Benzimidazoles; Bi | 2005 |
Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2000 |
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
8 other studies available for candesartan cilexetil and Albuminuria
Article | Year |
---|---|
Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2015 |
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
Topics: Administration, Oral; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2008 |
Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2004 |
Renal protective effect of TCV-116 in stroke-prone spontaneously hypertensive rats.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Ben | 1994 |
Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat.
Topics: Albuminuria; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzi | 1993 |
Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; | 1997 |
Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Bip | 1999 |
Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Be | 2002 |